By binding to PD-L1, Avelumab blocks its interaction with the PD-1 receptor on T-cells, thereby preventing the deactivation of the antitumor immune response and effectively allowing cytotoxic T-lymphocytes to kill cancer cells [11]. This evidence concerns the gene CD274 and cancer.